Join the Oncology Voice Network. Join for Free
Professional Development: Why Consider an Executive Coach
Life Reset Labs Dana Paskalis coaching in professional development career coaching executive coach advice

Professional Development: Why Consider an Executive Coach


Share This Article


Summary

In this episode, Dana Paskalis, founder of Life Reset Labs, joins to discuss the pivotal role of coaching in personal and professional development. Dana outlines her career path leading to the creation of her coaching company and highlights the significance of self-talk and mindset in advancing one's career. She explores the differences between a mentor and a coach, offering advice on when to seek professional guidance. The conversation also covers the impact of company culture and handling layoffs, alongside strategies for proactive career planning. The episode concludes with a reminder to subscribe for more insights.

Today’s guest is Dana Paskalis, CEO and Founder of Life Reset Labs and we discuss why professionals should consider an executive or career coach
Dana discusses….

๐Ÿ‘‰ What led her to transition to a Certified Coach and Life Strategist
๐Ÿ‘‰ What exactly a Certified Coach and Life Strategist does
๐Ÿ‘‰ What is the difference between a coach and a mentor
๐Ÿ‘‰ Who should consider a coach (and who doesn’t need a coach)
๐Ÿ‘‰ Tips and career advice for MSLs
๐Ÿ‘‰ Tips and advice for finding success in 2023

Click for Source
Life Reset Labs, Dana Paskalis, coaching in professional development, career coaching, executive coach advice

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Article
AI-powered real-world evidence: Strategically enhancing value and access
Partner Avatar Envision Pharma Group

AI-powered real-world evidence: Strategically enhancing value and access

Explore OVN